



# **REGULATION OF LIMB DEVELOPMENT BY FIBROBLAST GROWTH FACTOR (FGF) SYSTEM**


**Pavel Krejci**

4 receptors: FGFR1-4  
22 ligands: FGF1-23







Initiation: *Tbx5* - dependent





## A Induction





## B Progression




Outgrowth: *Tbx5* - independent








**a** Normal FL and HL




AER KO mutant phenotypes

**b** *Fgf8* single KO FL



**c** *Fgf4; Fgf8* double KO FL




**d** *Fgf8* single KO HL




**e** *Fgf4; Fgf8* double KO HL





# How do the limbs grow?



# **FGFR3**





# FGFR3-related skeletal dysplasia


STATURE

Hypochondroplasia


Achondroplasia

SADDAN

Thanatophoric Dysplasia




# FGFR3-related skeletal dysplasia



Achondroplasia


# Thanatophoric Dysplasia



**healthy**



**TD**



- short long bones
- brachydactyly
- macrocephaly
- low nasal bridge
- spinal stenosis
- temporal lobe malformations




Loss-of-function

vs. Gain-of-function







**healthy**





**TD**


# FGFR3 inhibits chondrocyte proliferation by arresting their cell cycle in G1 phase




....via inhibition of cdk activity necessary for progression through the G1 phase of a cell cycle






# FGF alters the cartilage-like phenotype of chondrocytes




.....via MMP-mediated degradation of extracellular matrix






# FGF2 activates Erk and p38 MAPK, PLC $\gamma$ and PKB in chondrocytes




	1'	5'	30'	1h	4h	6h	12h	18h	24h	0h	4h	12h
F	F	F	F	F	F	F	F	F	F	-	-	H
F/H	-	-	H									




.....but only Ras/Erk activity is involved in FGF-induced growth arrest




# Erk MAP kinase activity is necessary for FGFR3 phenotype in cartilage




C-type Natriuretic Peptide (CNP) over-expression results in skeleton overgrowth in mice



wild-type




CNP↑



CNP over-expression???

# CNP rescues dwarfism caused by ACH mutation in FGFR3




wild-type


*Fgfr3*<sup>Ach</sup>

*Fgfr3*<sup>Ach/CNP</sup> ↑

# CNP counteracts FGF2-mediated chondrocyte growth arrest through cGMP-dependent pathway



# CNP antagonizes FGF2-mediated loss of cartilage extracellular matrix in chondrocytes



# CNP counteracts FGF2-mediated activation of Erk MAP kinase in chondrocytes

FGF2



FGFR3



FRS2



Ras



Raf-1



MEK




Erk

FGF2	-	+	+	+	+	-	-	+	+	+	+	+	-	FGF2
	-	-	0.1	0.2	0.5	0.1	-	-	-	-	-	-	-	CNP [μM]
	-	-	-	-	-	-	-	-	-	-	-	-	-	pCPT-cGMP [μM]

P-Erk1/2



Erk1/2




FGF2    -    +    +    -

CNP    -    -    +    +    -Ab

IP: Raf-1

Raf-1




WB

P-MEK


FGF2    -    +    +    -

CNP    -    -    +    +    -


Raf-GST



Ras total




P-Erk1/2




P-Erk1/2




Erk1/2



Erk1/2



# CNP inhibits Erk MAP kinase module at the Raf level



# Is protein kinase C (PKC) involved in FGFR3-mediated activation of Erk in chondrocytes?

FGF2



FGFR3



FRS2



Ras



Raf-1



MEK




**Erk**

FGF2	-	+	+	+	+	-	+	+	+	-	-	+	+	+	+	-
------	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

Gö6983 (μM)	-	-	1	5	10	5	-	-	-	-	-	-	-	-	-	-
-------------	---	---	---	---	----	---	---	---	---	---	---	---	---	---	---	---

Bis I (μM)	-	-	-	-	-	-	1	5	10	5	-	-	-	-	-	-
------------	---	---	---	---	---	---	---	---	----	---	---	---	---	---	---	---

Gö6976 (μM)	-	-	-	-	-	-	-	-	-	-	-	-	1	5	10	5
-------------	---	---	---	---	---	---	---	---	---	---	---	---	---	---	----	---







FGF2	-	+	+	+	+	+	+	+	+	-
------	---	---	---	---	---	---	---	---	---	---

GFX (μM)	-	-	0.5	1	5	10	20	50	-	10
----------	---	---	-----	---	---	----	----	----	---	----


vehicle (DMSO)	-	-	+	+	+	+	+	+	+	+
----------------	---	---	---	---	---	---	---	---	---	---

kinase









Protein kinase C inhibitor Bisindolylmaleimide I (Bis I) suppresses the FGF2-mediated activation of Erk MAP kinase pathway in chondrocytes by preventing the SHP2 association with FRS2 and Gab1 adaptor proteins




# FGFR3 associates with STAT1 and acts as STAT1-kinase in chondrocytes




# Chronic FGF stimulus inhibits cytokine/STAT signaling in chondrocytes




# Chronic FGF stimulus inhibits cytokine/STAT signaling in chondrocytes



# FGF2 causes premature senescence in chondrocytes



# FGF2 signals towards the cytoskeleton in chondrocytes




# Where is Wnt?




FGF2: C1 15' 1h 3h 6h 12h 24h 48h 72h C2 C3


*b*-catenin



actin



2001



NOW

